23 New and approved therapies for lupus nephritis: Belimumab and voclosporin

Bibliographic Details
Main Author: Richard Furie
Format: Article
Language:English
Published: BMJ Publishing Group 2022-04-01
Series:Lupus Science and Medicine
_version_ 1818364902655393792
author Richard Furie
author_facet Richard Furie
author_sort Richard Furie
collection DOAJ
first_indexed 2024-12-13T22:11:45Z
format Article
id doaj.art-2cd6071f5c3749feb9df88c7f4a73955
institution Directory Open Access Journal
issn 2053-8790
language English
last_indexed 2024-12-13T22:11:45Z
publishDate 2022-04-01
publisher BMJ Publishing Group
record_format Article
series Lupus Science and Medicine
spelling doaj.art-2cd6071f5c3749feb9df88c7f4a739552022-12-21T23:29:42ZengBMJ Publishing GroupLupus Science and Medicine2053-87902022-04-019Suppl 110.1136/lupus-2022-la.2323 New and approved therapies for lupus nephritis: Belimumab and voclosporinRichard Furie02 Division of Rheumatology, Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Great Neck, New York, USA
spellingShingle Richard Furie
23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
Lupus Science and Medicine
title 23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
title_full 23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
title_fullStr 23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
title_full_unstemmed 23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
title_short 23 New and approved therapies for lupus nephritis: Belimumab and voclosporin
title_sort 23 new and approved therapies for lupus nephritis belimumab and voclosporin
work_keys_str_mv AT richardfurie 23newandapprovedtherapiesforlupusnephritisbelimumabandvoclosporin